1988
The role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1984
25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE
DeVita V, Goidin A. 25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE. 1984, 499-526. DOI: 10.1016/b978-0-12-667980-9.50032-4.Peer-Reviewed Original ResearchCombination of drugsTypes of tumorsNational Cancer InstituteGroup of diseasesDosage scheduleCancer therapistClinical oncologistsCancer InstituteExperimental animalsBeneficial effectsTherapeutic researchTumorsDrugsTreatmentSignificant numberField of medicineRemissionChemotherapyPatientsSurgeryOncologistsRadiotherapyCancerDiseasePhysicians
1983
Progress in cancer management. Keynote address
Devita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsCancer managementUtility of radiotherapyUse of radiotherapyCancer cure ratesWorld War IIEradication of cancerManagement of cancerPrime therapeutic targetFirst chemotherapyNational Cancer ActBlood transfusionLocal recurrenceMedical oncologistsTreatment failureRecurrent cancerCure rateWar IIEffective treatmentTherapeutic targetPatientsRadiotherapySurgerySuch toxicitySerious cancersCancerAdvances in cancer therapeutics: chemotherapy.
DeVita V. Advances in cancer therapeutics: chemotherapy. Progress In Clinical And Biological Research 1983, 132A: 47-69. PMID: 6634746.Peer-Reviewed Original ResearchConceptsTumor massEffectiveness of combination chemotherapyResistance to anti-cancer drugsCancer chemotherapyInvariable inverse relationshipPathways of drug resistanceOutcome of cancer chemotherapyOutcome of surgeryResistance to chemotherapyCell numberHistory of cancerNatural history of cancerOrigin of human cancerCombination chemotherapyAnti-cancer drugsLocal treatmentChemotherapyDrug resistanceHuman malignanciesRadiotherapyCancer therapeuticsNatural historyHuman cancersSurgeryCancer
1982
Immunological and physiological responses to whole-body hyperthermia.
Bull J, Lees D, Schuette W, Smith R, Glatstein E, DeVita V. Immunological and physiological responses to whole-body hyperthermia. National Cancer Institute Monograph 1982, 61: 177-81. PMID: 7177176.Peer-Reviewed Original Research
1978
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Johnson R, Canellos G, Young R, Chabner B, DeVita V. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Journal Of The National Cancer Institute 1978, 62: 321-5. PMID: 580598.Peer-Reviewed Original ResearchConceptsTotal body irradiationTotal body irradiation patientsEvaluate new therapeutic approachesSurvival rateStage III-IVCandida sepsisDurable remissionsLymphocytic lymphomaBody irradiationMalignant lymphomaSevere granulocytopeniaMyeloproliferative disordersLate complicationsIII-IVChemotherapy complicationsInduction treatmentSurvival advantageNeurotoxic reactionsTherapeutic approachesLymphomaChemotherapyPatientsComplicationsRadiotherapySurvival
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograft
1975
Peritoneoscopy: a valuable staging tool in ovarian carcinoma.
Rosenoff S, Young R, Anderson T, Bagley C, Chabner B, Schein P, Hubbard S, DeVita V. Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Annals Of Internal Medicine 1975, 83: 37-41. PMID: 125057, DOI: 10.7326/0003-4819-83-1-37.Peer-Reviewed Original ResearchConceptsOvarian carcinomaApparent clinical remissionValuable staging toolAdvanced diseaseClinical remissionExploratory laparotomyConsecutive patientsDiaphragmatic involvementPretreatment evaluationAbdominal radiotherapyTherapeutic failureLaboratory examinationsStaging toolPatientsCarcinomaLiver areaLaparotomyPeritoneoscopySecond lookPercentRemissionRadiotherapyRoentgenologicTherapyPelvisSECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION
Canellos G, Arseneau J, Devita V, Whang-Peng J, Johnson R. SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet 1975, 305: 947-949. PMID: 48122, DOI: 10.1016/s0140-6736(75)92007-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellChromosome AberrationsColonic NeoplasmsFemaleFibrosarcomaHodgkin DiseaseHumansImmunosuppression TherapyLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteLung NeoplasmsMaleMiddle AgedNeoplasmsNeoplasms, Radiation-InducedRadiotherapyRemission, SpontaneousSkin NeoplasmsConceptsIntensive radiotherapyCombination chemotherapyPatients treated with standard chemotherapyCourse of Hodgkin's diseaseRelapse of diseaseAcute myeloid leukemiaMan-years of follow-upMode of treatmentMechanisms of oncogenesisStandard chemotherapyHodgkin's diseaseChromosomal abnormalitiesMyeloid leukemiaImmunosuppressive effectsRadiotherapyFollow-upChemotherapyTumorHigh riskCellular effectsPatientsDiseaseIncidenceTreatmentRisk
1974
The design of clinical trials in the therapy of ovarian carcinoma
Young R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.Peer-Reviewed Original ResearchConceptsOvarian carcinomaClinical trialsProspective randomized clinical trialsSurvival of patientsCombined modality approachRandomized clinical trialsPrognostic factorsStandardized stagingModality approachTherapySuch trialsCarcinomaMajor causeTrialsPatientsBase lineSurvivalChemotherapyRadiotherapyStagingWomen
1973
Hodgkin's Disease in Childhood
Young R, DeVita V, Johnson R. Hodgkin's Disease in Childhood. Blood 1973, 42: 163-174. PMID: 4793108, DOI: 10.1182/blood.v42.2.163.163.Peer-Reviewed Original ResearchOvarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy A preliminary report
Bagley C, Young R, Schein P, Chabner B, Devita V. Ovarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy A preliminary report. American Journal Of Obstetrics And Gynecology 1973, 116: 397-400. PMID: 4267636, DOI: 10.1016/s0002-9378(15)31299-0.Peer-Reviewed Original ResearchConceptsDiaphragmatic metastasisOvarian carcinomaOvarian carcinoma metastaticStage IA diseaseUpper abdominal metastasisIA diseaseAbdominal metastasesCarcinoma metastaticHigh incidenceMetastasisPatientsCarcinomaPreliminary reportRadiotherapyOnly siteDirect visualizationDiaphragmLaparotomyMetastaticPeritoneoscopyIncidenceDiseasePhysiciansLiverWeeks
1972
Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy
Arseneau J, Sponzo R, Levin D, Schnipper L, Bonner H, Young R, Canellos G, Johnson R, DeVita V. Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy. New England Journal Of Medicine 1972, 287: 1119-1122. PMID: 5082192, DOI: 10.1056/nejm197211302872204.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellCyclophosphamideDrug-Related Side Effects and Adverse ReactionsFemaleFibrosarcomaFollow-Up StudiesHead and Neck NeoplasmsHodgkin DiseaseHumansMaleMiddle AgedNeoplasm MetastasisNeoplasmsNeoplasms, Radiation-InducedNitrogen Mustard CompoundsPrednisoneProcarbazineRadiotherapyRemission, SpontaneousTime FactorsVincristineConceptsHodgkin's diseaseMalignant tumorsIntensive radiotherapyIntensive chemotherapyBiopsy-proven malignant tumorsTime of diagnosisSecond malignant tumorsRisk of developmentBasis of treatmentBasis of ageIntensive therapyCase recordsChemotherapyDiseasePatientsRadiotherapyTumorsGreater increaseSubgroupsRiskTherapyIncidenceDiagnosisCombination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
Canellos G, Young R, DeVita V. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology & Therapeutics 1972, 13: 750-754. PMID: 5053816, DOI: 10.1002/cpt1972135part1750.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyProlonged disease-free intervalExtensive radiation therapyAdvanced Hodgkin's diseaseDisease-free intervalEnd of radiotherapyOnset of chemotherapyCombination chemotherapy programsDegree of myelosuppressionExtensive radiotherapyIntensive radiotherapyCurative intentComplete remissionExtensive diseasePrevious radiotherapyRemission rateChemotherapy programRadiation therapyDrug toxicityPatientsRadiotherapyMonthly cyclesChemotherapyDisease
1970
Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease
LOWENBRAUN S, DEVITA V, SERPICK A. Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease. Blood 1970, 36: 704-717. PMID: 5488687, DOI: 10.1182/blood.v36.6.704.704.Peer-Reviewed Original ResearchConceptsCombination chemotherapyPrior radiotherapyHodgkin's diseaseProgressive Hodgkin's diseaseStage IV diseaseRemission 1Previous therapyComplete responseNitrogen mustardPartial responseTherapy completionSystemic symptomsDrug combinationsChemotherapyPatientsDay 1Drug AdministrationRadiotherapyPrednisoneDiseasePoor toleranceVincristineCycle 1TherapyI.V.